Our design provides an alternative method to non-invasively assess EGFR information and to assist in decision-making when applying TKI as an initial treatment in inoperable or inappropriate situations for surgical treatment of lung adenocarcinoma manifesting as pGGN. Here, EGFR is linked to lung adenocarcinoma.